Symptom-specific TMS Targets for Depression and Anxiety

Brigham and Women's Hospital40 enrolled

Overview

This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.

Transcranial magnetic stimulation (TMS) is a safe, noninvasive FDA-cleared technique that is commonly used as a treatment for MDD. It has been shown to focally activate specific brain regions that are believed to be underactive in these patients. This study aims to compare two different TMS targets in the prefrontal cortex. TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. This will be a prospective double-blind randomized controlled trial to assess the comparative efficacy of two different TMS targets within the prefrontal cortex (PFC). The "dysphoric" target in the dorsolateral PFC is believed to be more effective for depression, while the "anxiosomatic" target in the dorsomedial PFC is believed to be more effective for anxiety. Patients with comorbid depression and anxiety will receive 6 weeks of TMS following standard clinical parameters (30 treatments over 6 weeks, 10 Hz frequency, 3000 pulses) with MRI-guided neuronavigation. Participants will be randomized to either the dysphoric or anxiosomatic target. Both targets are believed to be effective treatments for this patient population. Participants and raters will remain blinded to the group assignment. All participants will receive resting-state functional MRI scans before and after the course of treatment in order to study physiological changes. The dysphoric target is expected to induce greater relative improvement in depression, while the anxiosomatic target is expected to induce greater relative improvement in anxiety.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Depression Anxiety Major Depressive Disorder

Interventions

Transcranial magnetic stimulationPROCEDURE

Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults age 18 to 65 * Meeting FDA guidelines for clinical TMS (DSM-5 diagnosis of major depressive disorder with at least one failed antidepressant trial)1 * Beck Depression Inventory (BDI) score of 20 or higher * Beck Anxiety Inventory (BAI) score of 16 or higher Exclusion Criteria: * History of: * Moderate or severe substance use disorder in the past six months as defined by DSM-5 criteria, with the exception of cannabis and nicotine use disorders. * Dementia, as defined by treating neurologist * Moderate or severe autism spectrum disorder * Bipolar disorder * Schizophrenia spectrum disorders * Current evidence of: * Substance-induced mood disorder * Active psychotic symptoms * Active suicidal ideation * Contraindications to rTMS treatment: * Seizure disorder * Significantly elevated seizure risk, as determined by clinician assessment * Presence of metallic objects within the head * Presence of an implanted neurostimulation device within the head * Contraindications to MRI * Severe claustrophobia * Severe pain/illness exacerbated by lying prone in the scanner * Presence of non-MRI compatible metal foreign bodies or implants * Weight in excess of 350 lbs * Shoulder width in excess of maximum tolerable width for scanner

Locations (1)

Brigham & Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Beck Anxiety Inventory (BAI)

The primary outcome will be the rank-transformed ratio of BDI change to BAI change

Time frame: Baseline (before treatment), 3 weeks (after 15 treatments), and 6 weeks (after 30 treatments)

Beck Depression Inventory (BDI)

The primary outcome will be the rank-transformed ratio of BDI change to BAI change

Time frame: Baseline (before treatment), 3 weeks (after 15 treatments), and 6 weeks (after 30 treatments)

Secondary Outcomes

Resting-state functional MRI (rsfMRI) scan

Functional MRI scan will be conducted before and after treatment in order to assess for treatment-induced changes in brain connectivity

Time frame: Baseline (before treatment) and 6 weeks (after 30 treatments)

Temperament and Character Inventory, Revised 140-item (TCI-R 140)

Psychobiologically-based personality inventory which measures seven personality dimensions (harm avoidance, novelty seeking, reward dependence, persistence, self-directedness, cooperativeness, and persistence). For each dimension, this yields a scaled T-score (mean score of 50 with standard deviation of 10). This is an overall estimate of personality traits, and there are no "better" or "worse" traits.

Time frame: Baseline (before treatment) and 6 weeks (after 30 treatments)

NIH Toolbox cognitive battery

An interactive computerized battery of cognitive tasks which is used to compute an overall index of crystallized and fluid cognition. For each cognitive subscale, this yields a scaled T-score (mean score of 100 with standard deviation of 10).

Time frame: Baseline (before treatment) and 6 weeks (after 30 treatments)

Multidimensional task-based emotional assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.